Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
1-A
1-A POS
1-A-W
1-A/A
1-K
1-K/A
1-SA
1-SA/A
1-U
1-U/A
1-Z
1-Z-W
1-Z/A
1/A
10-12B
10-12B/A
10-12G
10-12G/A
10-D
10-D/A
10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QSB
10-QSB/A
10-QT
10-QT/A
10KSB
11-K
11-K/A
11-KT
13F-HR
13F-HR/A
13F-NT
13F-NT/A
13FCONP
144
144/A
15-12B
15-12B/A
15-12G
15-12G/A
15-15D
15-15D/A
15F-12B
15F-12G
15F-12G/A
15F-15D
18-K
18-K/A
19B-4E
2-E
20-F
20-F/A
20FR12B
20FR12B/A
20FR12G/A
24F-2NT
24F-2NT/A
25
25-NSE
25-NSE/A
25/A
253G1
253G2
253G3
3
3/A
305B2
305B2/A
4
4/A
40-17F1
40-17F1/A
40-17F2
40-17F2/A
40-17G
40-17G/A
40-202A
40-202A/A
40-206A
40-24B2
40-33
40-6B
40-6B/A
40-6C
40-6C/A
40-8B25
40-8F-2/A
40-APP
40-APP/A
40-F
40-F/A
40-OIP
40-OIP/A
40FR12B
40FR12B/A
424B1
424B2
424B3
424B4
424B5
424B7
424B8
424H
424H/A
425
485APOS
485B24E
485BPOS
485BXT
486APOS
486BPOS
486BXT
487
497
497AD
497J
497K
5
5/A
6-K
6-K/A
8-A12B
8-A12B/A
8-A12G
8-A12G/A
8-K
8-K/A
8-K12B
8-K12B/A
8-K12G3
8-K12G3/A
8-K15D5
8-K15D5/A
8-M
9-M
ABS-15G
ABS-15G/A
ABS-EE
ABS-EE/A
ADV-E
ADV-H-C
ADV-H-T
ADV-NR
ANNLRPT
APP NTC
APP ORDR
APP WD
APP WD/A
ARS
ARS/A
ATS-N
ATS-N/CA
ATS-N/MA
ATS-N/UA
AW
AW WD
C
C-AR
C-AR-W
C-AR/A
C-TR
C-U
C-U-W
C-W
C/A
C/A-W
CB
CB/A
CERT
CERTARCA
CERTBATS
CERTCBO
CERTNAS
CERTNYS
CERTPAC
CFPORTAL
CFPORTAL/A
CORRESP
CT ORDER
D
D/A
DEF 14A
DEF 14C
DEF13E3
DEF13E3/A
DEFA14A
DEFA14C
DEFC14A
DEFC14A
DEFC14C
DEFM14A
DEFM14C
DEFN14A
DEFR14A
DEFR14C
DEFS14A
DEFS14C
DEL AM
DFAN14A
DFRN14A
DOS/A
DSTRBRPT
DSTRBRPT/A
EFFECT
F-1
F-1/A
F-10
F-10/A
F-10EF
F-1MEF
F-3
F-3/A
F-3ASR
F-3D
F-4
F-4/A
F-6
F-6 POS
F-6/A
F-6EF
F-7
F-8 POS
F-80
F-N
F-X
F-X/A
FOCUSN
FOCUSN/A
FWP
G-405
G-FIN/A
IRANNOTICE
MA
MA-A
MA-I
MA-I/A
MA-W
MA/A
MSD
MSD/A
N-14
N-14 8C
N-14 8C/A
N-14/A
N-14MEF
N-18F1
N-1A
N-1A/A
N-2
N-2/A
N-23C-2
N-23C3A
N-23C3B
N-2MEF
N-30B-2
N-30D
N-30D/A
N-4
N-4/A
N-54A
N-54C
N-6
N-6/A
N-6F
N-8A
N-8A/A
N-8B-2/A
N-8F
N-8F NTC
N-8F ORDR
N-8F/A
N-CEN
N-CEN/A
N-CSR
N-CSR/A
N-CSRS
N-CSRS/A
N-MFP2
N-MFP2/A
N-PX
N-PX/A
N-Q
N-Q/A
NO ACT
NPORT-P
NPORT-P/A
NRSRO-CE
NRSRO-CE/A
NRSRO-UPD
NSAR-A
NSAR-A/A
NSAR-AT
NSAR-B
NSAR-B/A
NSAR-BT
NSAR-U
NSAR-U/A
NT 10-K
NT 10-K/A
NT 10-Q
NT 10-Q/A
NT 11-K
NT 20-F
NT 20-F/A
NT N-CEN
NT N-MFP2
NT NPORT-EX
NT-NCSR
NT-NCSR/A
NT-NSAR
NT-NSAR/A
NTFNCSR
NTN 10Q
POS 8C
POS AM
POS AMI
POS EX
POS462B
POSASR
PRE 14A
PRE 14C
PREC14A
PREC14C
PREM14A
PREM14C
PREN14A
PRER14A
PRER14C
PRRN14A
PX14A6G
QRTLYRPT
QUALIF
REG-NR
REGDEX
REGDEX/A
REVOKED
RW
RW WD
S-1
S-1/A
S-11
S-11/A
S-11MEF
S-1MEF
S-1MEF
S-3
S-3/A
S-3ASR
S-3D
S-3DPOS
S-3MEF
S-4
S-4 POS
S-4/A
S-4MEF
S-6
S-6/A
S-8
S-8 POS
S-B
S-B/A
SC 13D
SC 13D/A
SC 13E
SC 13E/A
SC 13E1
SC 13E1/A
SC 13E3
SC 13E3/A
SC 13E4
SC 13E4/A
SC 13G
SC 13G/A
SC 14D9
SC 14D9/A
SC 14F1
SC TO-C
SC TO-I
SC TO-I/A
SC TO-T
SC TO-T/A
SC14D9C
SD
SD/A
SDR/A
SE
SEC STAFF
SEC STAFF ACTION
SEC STAFF LETTER
SF-1/A
SF-3
SF-3/A
SUPPL
T-3
T-3/A
TA-1
TA-1/A
TA-2
TA-2/A
TA-W
UPLOAD
WDL-REQ
X-17A-5
X-17A-5/A
Tags
Inv. presentation
Quarterly results
Day One Biopharmaceuticals, Inc.
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/16/2023
8-K
Investor presentation
Docs:
"
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
",
"
Corporate Presentation
"
08/07/2023
8-K
Investor presentation, Quarterly results
Docs:
"
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress Results from FIREFLY-1 demonstrate overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma evaluable patients presented at the 2023 American Society of Clinical Oncology Annual Meeting Initiated rolling submission of the tovorafenib New Drug Application in relapsed or progressive pediatric low-grade glioma in May 2023 The Company expects to complete the rolling submission of the tovorafenib NDA by October 2023 Completed $172.5 million public offering, strengthening balance sheet and extending cash runway into 2026
",
"
2 PO QW DAY101 QW
"
06/12/2023
8-K
Investor presentation
Docs:
"
Corporate Presentation
"
05/01/2023
8-K
Investor presentation, Quarterly results
Docs:
"
Day One Reports First Quarter 2023 Financial Results and Corporate Progress FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting Leadership team strengthened with executive appointments in clinical development and commercialization Pre-New Drug Application meeting held April 19, 2023 with U.S. Food and Drug Administration for tovorafenib for relapsed or progressive pediatric low-grade glioma Company to host conference call on June 4th at 6:00 PM CT
",
"
2 PO QW DAY101 QW
"
03/20/2023
8-K
Quarterly results
03/06/2023
8-K
Investor presentation, Quarterly results
Docs:
"
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for presentation at a medical meeting in second quarter of 2023 New Drug Application submission planned for tovorafenib in first half of 2023
",
"
2 PO QW DAY101 QW
"
01/09/2023
8-K
Investor presentation
Docs:
"
Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib in Recurrent or Progressive Pediatric Low-Grade Glioma
",
"
Corporate Presentation
"
11/07/2022
8-K
Investor presentation, Quarterly results
Docs:
"
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress Topline results for full pivotal FIREFLY-1study population with tovorafenib in relapsed or progressive pediatric low-grade glioma are expected in the first quarter of 2023 Strengthened leadership team with key appointments to senior management team and board of directors SOUTH SAN FRANCISCO, Calif., November 7, 2022 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced financial results for the third quarter of 2022 and highlighted recent corporate achievements. “Day One’s progress in 2022 has been remarkable. We announced positive interim results from our ...
",
"
2 PO QW DAY101 QW
"
09/12/2022
8-K
Investor presentation
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
",
"
Day One Appoints Garry Nicholson as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., September 12, 2022 - Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors. “Garry is an accomplished leader in the development and commercialization of ne...
",
"
Corporate Presentation
"
08/04/2022
8-K
Quarterly results
06/24/2022
8-K
Quarterly results
06/13/2022
8-K
Investor presentation
Docs:
"
Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib in Relapsed Pediatric Low-Grade Glioma
",
"
FIREFLY-1 Interim Data Presentation
"
05/12/2022
8-K
Quarterly results
04/13/2022
8-K
Investor presentation
Docs:
"
II BRAF V600E ATP BRAF V600E
"
01/05/2022
8-K
Investor presentation
Docs:
"
Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, CA, January 5, 2022 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. ET. A live audio webcast of the presentation will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation. Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicat...
",
"
II BRAF V600E ATP BRAF V600E
"
11/03/2021
8-K
Investor presentation
Docs:
"
Day One Announces Presentation at 2021 Connective Tissue Oncology Society Virtual Annual Meeting  Compassionate use case of DAY101 demonstrates a complete response in a pediatric patient with a recurrent spindle cell sarcoma harboring a BRAF gene fusion SOUTH SAN FRANCISCO, CA, November 3, 2021 – Day One Biopharmaceuticals , a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced an upcoming poster presentation at the 2021 Connective Tissue Oncology Society Virtual Annual Meeting, being held from November 10-13, 2021. The poster reviews a compassionate use case of a child with recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion who had exha...
",
"
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 NH2 COOH BRAF
"
08/10/2021
8-K
Quarterly results
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy